| Patient | Susan B. Anthony |
|---|---|
| Date of birth | 1941-02-15 |
| Identifiers | MRN HR-NI014-SYN; SSN (made up) 000-14-7302 |
| Document date | 2026-06-29 |
| Author | Harold Pemberton, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month heart failure and blood pressure review. [S]
Miss Anthony returns for her three-month review. She has had no swelling for six weeks and climbs stairs without stopping. Her morning weight has held at 56.0 to 56.4 kg for a month. She has resumed a reduced lecture schedule and walks a mile a day. She has had no dizziness on spironolactone, no breast tenderness, and no muscle cramps. She asks whether she still needs the daily water pill, because it limits her travel. [S]
| Element | Detail |
|---|---|
| Interval change | No edema for six weeks; stairs without stopping |
| Weight diary | Stable at 56.0 to 56.4 kg for a month |
| Medication tolerance | No dizziness, breast tenderness, or cramps on spironolactone |
| Function | Walking a mile a day; reduced lecture schedule |
| Patient goal | Fewer diuretic days so she can travel |
| NYHA class | I to II |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improved; no weight gain |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or edema |
| Respiratory | Negative | Breathless only on long climbs |
| Genitourinary | Positive | Urgency on diuretic mornings; no dysuria |
| Neurological | Negative | No dizziness on standing |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-16 to 2026-06-29 | completed | S |
| Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a week | One tablet by mouth once daily as needed for weight gain | Oral route | 2026-06-29 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-16 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 2026-03-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-29 | Body height | 165 | cm | S |
| 2026-06-29 | Body weight | 56.2 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 72 | /min | S |
| 2026-06-29 | Respiratory rate | 16 | /min | S |
| 2026-06-29 | Body temperature | 36.7 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-29 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 720 | pg/mL | <=125 pg/mL | High | S |
| 2026-06-29 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 61 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-29 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-06-29 | Overall summary score [KCCQ-12] | 70 | {score} | S | ||
| 2026-06-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, energetic |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm; soft S4 |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1906 heart failure | active | confirmed | I50.32 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode; the 1906 cause of death remains D. |
| Hypertensive heart disease with heart failure | active | confirmed | I11.0 | S — Synthetic diagnosis; no blood pressure from her lifetime is recorded in the cited sources. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel with magnesium | 1 to 2 weeks after starting or changing therapy; every 3 to 6 months when stable | Completed today | Potassium 4.5, eGFR 61. This is the first panel since spironolactone started three months ago |
| Laboratory | Basic metabolic panel 1 to 2 weeks after starting spironolactone | Once, after starting a mineralocorticoid antagonist | Deferred | Not drawn in the two-week window, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted; the reminder is now in her chart |
| Laboratory | NT-proBNP | Selectively in outpatient follow-up | Completed today | 720 pg/mL, down from 1650; informs decongestion, not used to titrate therapy |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit | Completed today | Euvolemic at 56.2 kg |
| Survey | NYHA functional class | Every visit | Completed today | Class I to II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 70, up 18 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Completed today | Score 0 |
| Imaging | Echocardiogram | Only with unexplained clinical change | Not indicated | Improving as expected; routine repeat imaging is not recommended |
| Referral | Cardiac rehabilitation | If exercise tolerance plateaus | Not indicated | Exercise tolerance still improving with daily walking |
| Self-management | Daily weight diary and travel plan | Every visit | Completed today | Travel weight plan written today |
Goal progress:
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026)
Follow-up: Six-month heart failure review with a basic metabolic panel and KCCQ-12. Next scheduled visit 2026-09-28: six-month heart failure review. [S]